Innovative Treatment Strategy for Glioblastoma Emerges
Researchers at the University of Calgary are exploring an experimental therapy for glioblastoma, an exceptionally aggressive brain cancer, using large doses of vitamin B3, also known as niacin. Early animal studies demonstrated that niacin helps rejuvenate immune cells, enhancing their ability to combat tumors and extending survival. In a clinical trial involving 24 patients, results showed encouraging outcomes: after six months, 82% of participants experienced no tumor progression. This rate surpasses standard treatment success by 28%, where conventional care typically involves surgery combined with radiation and chemotherapy.
Leadership and Findings of the Study
The study is led by oncologist Gloria Roldan Urgoiti and neurobiologist Vi Yong from the Hotchkiss Brain Institute. Patients receive controlled-release niacin alongside chemotherapy and radiation therapy. It is crucial to highlight that administering high doses of vitamin B3 requires careful medical supervision due to potential toxicity. The final evaluation of the trial's data is expected between late 2026 and early 2027.
According to the University of Calgary team,
"Glioblastoma suppresses the immune system, but treatment with niacin effectively revitalizes immune cells, enabling them to aggressively target the tumor again,"explains Gloria Roldan Urgoiti. This breakthrough offers hope for improving survival rates and quality of life in brain cancer patients.
Given glioblastoma's historically poor prognosis and limited treatment options, these findings could mark a significant advancement in care. The high percentage of patients showing halted disease progression opens new avenues for further research and potential changes in clinical protocols. The necessity of stringent monitoring to manage niacin's toxicity underscores the importance of expert medical oversight to ensure patient safety throughout therapy.